Video Upload Options

References

1. Aloia, L.; Di Stefano, B.; Di Croce, L. (2013). "Polycomb complexes in stem cells and embryonic development". Development 140 (12): 2525–34. doi:10.1242/dev.091553. PMID 23715546.  https://dx.doi.org/10.1242%2Fdev.091553
2. Armstrong, L (2014). Epigenetics. Garland Science. ISBN 9780815365112. 
3. Steffen, P.A.; Ringrose, L. (2014). "What are memories made of? How Polycomb and Trithorax proteins mediate epigenetic memory". Nat Rev Mol Cell Biol 15 (5): 340–356. doi:10.1038/nrm3789. PMID 24755934.  https://dx.doi.org/10.1038%2Fnrm3789
4. Sparmann, A.; van Lohuizen, M. (2006). "Polycomb silencers control cell fate, development and cancer". Nature Reviews Cancer 6 (11): 846–856. doi:10.1038/nrc1991. PMID 17060944.  https://dx.doi.org/10.1038%2Fnrc1991
5. Lee, N.; Maurange, C.; Ringrose, L.; Paro, R. (2005). "Suppression of Polycomb group proteins by JNK signalling induces transdetermination in Drosophila imaginal discs". Nature 438 (7065): 234–237. doi:10.1038/nature04120. PMID 16281037. Bibcode: 2005Natur.438..234L.  https://dx.doi.org/10.1038%2Fnature04120
6. Teschendorff, A.E.; Menon, U.; Gentry-Maharaj, A.; Ramus, S.J.; Weisen-berger, D.J.; Shen, H.; Campan, M.; Noushmehr, H. et al. (2010). "Age-dependent DNA methylation of genes that are sup- pressed in stem cells is a hallmark of cancer". Genome Res. 20 (4): 440–446. doi:10.1101/gr.103606.109. PMID 20219944.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2847747
7. Ohm, J.E.Expression error: Unrecognized word "etal". (2007). "A stem cell- like chromatin pattern may predispose tumor suppressor genes toDNAhyper- methylation and heritable silencing". Nat. Genet. 39 (2): 237–242. doi:10.1038/ng1972. PMID 17211412.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2744394
8. Widschwendter, M.; Fiegl, H.; Egle, D.; Mueller-Holzner, E.; Spizzo, G.; Marth, C.; Weisenberger, D.J.; Campan, M. et al. (2007). "Epigenetic stem cell signature in cancer". Nat. Genet. 39 (2): 157–158. doi:10.1038/ng1941. PMID 17200673.  https://dx.doi.org/10.1038%2Fng1941
9. Sauvageau, M.; Sauvageau, G. (2010). "Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer". Cell Stem Cell 7 (3): 299–313. doi:10.1016/j.stem.2010.08.002. PMID 20804967.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4959883
10. Benetatos, L.; Vartholomatos, G.; Hatzimichael, E. (2014). "Polycomb group proteins and MYC: the cancer connection". Cellular and Molecular Life Sciences 71 (2): 257–69. doi:10.1007/s00018-013-1426-x. PMID 23897499.  https://dx.doi.org/10.1007%2Fs00018-013-1426-x
11. Schuringa, JJ; Vellenga, E (2010). "Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells". Curr Opin Hematol 17 (4): 294–299. doi:10.1097/moh.0b013e328338c439. PMID 20308890.  https://dx.doi.org/10.1097%2Fmoh.0b013e328338c439
12. Lessard, J.; Sauvageau, G. (2003). "Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells". Nature 423 (6937): 255–260. doi:10.1038/nature01572. PMID 12714970. Bibcode: 2003Natur.423..255L.  https://dx.doi.org/10.1038%2Fnature01572
13. He, XTExpression error: Unrecognized word "etal". (2009). "Association between Bmi-1 and clinicopathological status of esophageal squamous cell carcinoma". World J Gastroenterol 15 (19): 2389–2394. doi:10.3748/wjg.15.2389. PMID 19452584.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2684608
14. Nowak, KExpression error: Unrecognized word "etal". (2006). "BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas". Nucleic Acids Res 34 (6): 1745–1754. doi:10.1093/nar/gkl119. PMID 16582100.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1421501
15. Shafaroudi, AM; Mowla, SJ; Ziaee, SA; Bahrami, AR; Atlasi, Y; Malakootian, M (2008). "Overexpression of BMI1 a polycomb group repressor protein in bladder tumors: a preliminary report". Urol J 5 (2): 99–105. PMID 18592462.  http://www.ncbi.nlm.nih.gov/pubmed/18592462
16. Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia" Blood 2007; 110: 380–383.
17. Crea, F; Duhagon Serrat, MA; Hurt, EM; Thomas, SB; Danesi, R; Farrar, WL (2011). "BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer". Int J Cancer 128 (8): 1946–1954. doi:10.1002/ijc.25522. PMID 20568112.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3265034
18. Siddique, HR; Saleem, M (2012). "Role of BMI1, a stem cell fac- tor, in cancer recurrence and chemoresistance: preclinical and clinical evidences". Stem Cells 30 (3): 372–378. doi:10.1002/stem.1035. PMID 22252887.  https://dx.doi.org/10.1002%2Fstem.1035
19. Zhang, Y.; Li, X.; Chen, Z.; Bepler, G. (2014). "Ubiquitination and degradation of ribonucleotide reductase M1 by the polycomb group proteins RNF2 and Bmi-1 and cellular response to gemcitabine". PLoS ONE 9 (3): 3. doi:10.1371/journal.pone.0091186. PMID 24614341. Bibcode: 2014PLoSO...991186Z.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3948819
20. Mills AA. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins" Nat Rev Cancer 2010; 10: 669–682.
21. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb EZH2 complex and histone deacetylase in prostate cancer" J Biol Chem 2005; 280: 22437–22444.
22. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression" Cell Death Differ 2010; 17: 801–810.
23. Hernández-Muñoz, I.; Lund, A. H.; van der Stoop, P.; Boutsma, E.; Muijrers, I.; Verhoeven, E.; van Lohuizen, M. (2005). "Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase". Proceedings of the National Academy of Sciences of the United States of America 102 (21): 7635–7640. doi:10.1073/pnas.0408918102. PMID 15897469.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1140410
24. Glickman, M. H.; Ciechanover, A. (2002). "The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction". Physiological Reviews 82 (2): 373–428. doi:10.1152/physrev.00027.2001. PMID 11917093.  https://dx.doi.org/10.1152%2Fphysrev.00027.2001
25. Cascón, A; Robledo, M (2012). "MAX and MYC: a heritable breakup". Cancer Res 72 (13): 3119–3124. doi:10.1158/0008-5472.can-11-3891. PMID 22706201.  https://dx.doi.org/10.1158%2F0008-5472.can-11-3891
26. Haupt, Y; Alexander, WS; Barri, G; Klinken, SP; Adams, JM (1991). "Novel zinc finger gene implicated as myc collaborator by retro- virally accelerated lymphomagenesis in E mu-myc transgenic mice". Cell 65 (5): 753–763. doi:10.1016/0092-8674(91)90383-a. PMID 1904009.  https://dx.doi.org/10.1016%2F0092-8674%2891%2990383-a
27. Van Lohuizen, M; Verbeek, S; Scheijen, B; Wientjens, E; van der Gulden, H; Berns, A (1991). "Identification of cooperating onco- genes in E mu-myc transgenic mice by provirus tagging". Cell 65 (5): 737–752. doi:10.1016/0092-8674(91)90382-9. PMID 1904008.  https://dx.doi.org/10.1016%2F0092-8674%2891%2990382-9
28. Liu Y, Liu F, Yu H, Zhao X, Sashida G, Deblasio A, Harr M, She QB, Chen Z, Lin HK, Di Giandomenico S, Elf SE, Yang Y, Miyata Y, Huang G, Menendez S, Mellinghoff IK, Rosen N, Pandolfi PP, Hedvat CV, Nimer SD (2012) Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus" Sci Signal 5:ra77.
29. Kaur, M; Cole, MD (2013). "MYC acts via the PTEN tumor sup- pressor to elicit auto regulation and genome-wide gene repres- sion by activation of the EZH2 methyltransferase". Cancer Res 73 (2): 695–705. doi:10.1158/0008-5472.can-12-2522. PMID 23135913.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3549058
30. Suvà, ML; Riggi, N; Janiszewska, M; Radovanovic, I; Provero, P; Stehle, JC; Baumer, K; Le Bitoux, MA et al. (2009). "EZH2 is essen- tial for glioblastoma cancer stem cell maintenance". Cancer Res 69 (24): 9211–9218. doi:10.1158/0008-5472.can-09-1622. PMID 19934320.  https://dx.doi.org/10.1158%2F0008-5472.can-09-1622
31. Shi, B; Liang, J; Yang, X; Wang, Y; Zhao, Y; Wu, H; Sun, L; Zhang, Y et al. (2007). "Integration of estrogen and Wnt signaling circuits by the polycomb group pro- tein EZH2 in breast cancer cells". Mol Cell Biol 27 (14): 5105–5119. doi:10.1128/mcb.00162-07. PMID 17502350.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1951944
32. Cai, MY; Tong, ZT; Zheng, F; Liao, YJ; Wang, Y; Rao, HL; Chen, YC; Wu, QL et al. (2011). "EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies". Gut 60 (7): 967–976. doi:10.1136/gut.2010.231993. PMID 21330577.  https://dx.doi.org/10.1136%2Fgut.2010.231993
33. Sasaki, M; Ikeda, H; Itatsu, K; Yamaguchi, J; Sawada, S; Minato, H; Ohta, T; Nakanuma, Y (2008). "The overexpression of polycomb group proteins Bmi-1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma". Lab Invest 88 (8): 873–882. doi:10.1038/labinvest.2008.52. PMID 18591938.  https://dx.doi.org/10.1038%2Flabinvest.2008.52
34. Sudo, T; Utsunomiya, T; Mimori, K; Nagahara, H; Ogawa, K; Inoue, H; Wakiyama, S; Fujita, H et al. (2005). "Clinicopathological significance of EZH2 mRNA expression in patients with hepato- cellular carcinoma". Br J Cancer 92 (9): 1754–1758. doi:10.1038/sj.bjc.6602531. PMID 15856046.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2362028
35. Au, SL; Wong, CC; Lee, JM; Fan, DN; Tsang, FH; Ng, IO; Wong, CM (2012). "Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis". Hepatology 56 (2): 622–631. doi:10.1002/hep.25679. PMID 22370893.  https://dx.doi.org/10.1002%2Fhep.25679
36. Cai, MY; Hou, JH; Rao, HL; Luo, RZ; Li, M; Pei, XQ; Lin, MC; Guan, XY et al. (2011). "High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients". Mol Med 17 (1–2): 12–20. doi:10.2119/molmed.2010.00103. PMID 20844838.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3022987
37. Cheng, AS; Lau, SS; Chen, Y; Kondo, Y; Li, MS; Feng, H; Ching, AK; Cheung, KF et al. (2011). "EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis". Cancer Res 71 (11): 4028–4039. doi:10.1158/0008-5472.can-10-3342. PMID 21512140.  https://dx.doi.org/10.1158%2F0008-5472.can-10-3342
38. Effendi, K; Mori, T; Komuta, M; Masugi, Y; Du, W; Sakamoto, M (2010). "Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression". Cancer Sci 101 (3): 666–672. doi:10.1111/j.1349-7006.2009.01431.x. PMID 20085590.  https://dx.doi.org/10.1111%2Fj.1349-7006.2009.01431.x
39. Wang, H; Pan, K; Zhang, HK; Weng, DS; Zhou, J; Li, JJ; Huang, W; Song, HF et al. (2008). "Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma". J Cancer Res Clin Oncol 134 (5): 535–541. doi:10.1007/s00432-007-0316-8. PMID 17917742.  https://dx.doi.org/10.1007%2Fs00432-007-0316-8
40. Forzati, F; Federico, A; Pallante, P; Abbate, A; Esposito, F; Malapelle, U; Sepe, R; Palma, G et al. (2012). "CBX7 is a tumor suppressor in mice and humans". J Clin Invest 122 (2): 612–623. doi:10.1172/jci58620. PMID 22214847.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3266782
41. Kleer, C. G.; Cao, Q.; Varambally, S.; Shen, R.; Ota, I.; Tomlins; Chinnaiyan, A. M. (2003). "EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells". Proceedings of the National Academy of Sciences of the United States of America 100 (20): 11606–11. doi:10.1073/pnas.1933744100. PMID 14500907. Bibcode: 2003PNAS..10011606K.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=208805
42. Peeters, Samantha D. (2014). "Variable escape from X chromosome inactivation: identifying factors that tip the scales towards expression". BioEssays 36 (8): 746–756. doi:10.1002/bies.201400032. PMID 24913292.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4143967
43. Herzing, LB; Romer, JT; Horn, JM; Ashworth, A (1997). "Xist has properties of the X-chromosome inactivation centre". Nature 386 (6622): 272–5. doi:10.1038/386272a0. PMID 9069284. Bibcode: 1997Natur.386..272H.  https://dx.doi.org/10.1038%2F386272a0
44. Portoso M, Cavalli G (2008). The Role of RNAi and Noncoding RNAs in Polycomb Mediated Control of Gene Expression and Genomic Programming. In Morris KV. RNA and the Regulation of Gene Expression: A Hidden Layer of Complexity. Caister Academic Press. pp. 29–44. ISBN:978-1-904455-25-7
45. Costanzi, Carl (2000). "Histone macroH2A1 is concentrated in the inactive X chromosome of female pre-implantation mouse emrbyos". Development 127: 2283–2289. 
46. Zhang, PExpression error: Unrecognized word "etal". (2015). "Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover". Cell Death & Disease 6 (3): e1687. doi:10.1038/cddis.2015.47. PMID 25766326.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4385925
47. Novikov, L. (2011). "QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation". Molecular and Cellular Biology 31 (20): 4244–4255. doi:10.1128/MCB.05244-11. PMID 21844227.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3187283
48. Constellation Pharmaceuticals. A Study Evaluating CPI-1205 in Patients with B-Cell Lymphomas. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 April 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT02395601?term=EZH2&rank=1. NLM Identifier: NCT02395601.
49. GlaxoSmithKline. A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 April 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT02082977?term=EZH2&rank=3. NLM Identifier: NCT02082977.
50. Raut, LS; Chakrabarti, PP (2014). "Management of relapsed-refractory diffuse large B cell lymphoma". South Asian Journal of Cancer 3 (1): 66–70. doi:10.4103/2278-330X.126531. PMID 24665451.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3961873
51. Eisai Limited. Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 April 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT01897571?term=EZH2&rank=2. NLM Identifier: NCT01897571.